Top News

Kite Pharma Surges In IPO

Los Angeles-based Kite Pharma, a biopharmaceuticals firm developing treatments for cancer, surged in its IPO this morning on the NASDAQ Global Market, trading as high as $29.22 in morning trading. The company had priced last night at $17.00 per share, above an earlier estimated initial public offering price of between $12.00 and $14.00 per share. Kite Pharma is venture backed by Pontifax, Alta Partners, and Commercial Street Capital, as well as financier David Bonderman. The company was up 68 percent in morning trading.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel